I F Walker1, S Kanal2, S C Baral2, T M Farragher3, D Joshi2, H Elsey1, J N Newell1. 1. Nuffield Centre for International Health and Development, University of Leeds, Leeds, UK. 2. Health Research and Social Development Forum, Kathmandu, Nepal. 3. Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Abstract
SETTING: Multidrug-resistant tuberculosis (MDR-TB) patients in the national TB treatment programme of Nepal. OBJECTIVE: To estimate the prevalence of depression and anxiety in people receiving treatment for MDR-TB, identify potential risk factors for depression and anxiety and determine temporal changes in their severity during treatment. DESIGN: An observational study using a screening tool, the Hopkins Symptom Checklist (HSCL-25) for depression and anxiety, administered monthly to a group of 135 patients in Nepal. Logistic and multilevel linear regression models were used to identify any patient characteristics associated with depression and anxiety. RESULTS: Most of the 135 patients were male (76%) and living with their families (68%). The period prevalences of depression and anxiety were respectively 22.2% and 15.6%. Patients reporting physical side effects of MDR-TB treatment had a higher depression score on HSCL by 2.63 points (95%CI 0.77-4.48) and a 1.59 point higher anxiety score (95%CI 0.45-2.73) than those who did not report any side effects. Being single was associated with having anxiety (aOR 0.2, 95%CI 0.03-1.0). CONCLUSION: Given the high rates of depression observed among MDR-TB patients, national TB treatment programmes should ensure their patients are routinely screened for depression and anxiety, and effective treatment offered.
SETTING: Multidrug-resistant tuberculosis (MDR-TB) patients in the national TB treatment programme of Nepal. OBJECTIVE: To estimate the prevalence of depression and anxiety in people receiving treatment for MDR-TB, identify potential risk factors for depression and anxiety and determine temporal changes in their severity during treatment. DESIGN: An observational study using a screening tool, the Hopkins Symptom Checklist (HSCL-25) for depression and anxiety, administered monthly to a group of 135 patients in Nepal. Logistic and multilevel linear regression models were used to identify any patient characteristics associated with depression and anxiety. RESULTS: Most of the 135 patients were male (76%) and living with their families (68%). The period prevalences of depression and anxiety were respectively 22.2% and 15.6%. Patients reporting physical side effects of MDR-TB treatment had a higher depression score on HSCL by 2.63 points (95%CI 0.77-4.48) and a 1.59 point higher anxiety score (95%CI 0.45-2.73) than those who did not report any side effects. Being single was associated with having anxiety (aOR 0.2, 95%CI 0.03-1.0). CONCLUSION: Given the high rates of depression observed among MDR-TB patients, national TB treatment programmes should ensure their patients are routinely screened for depression and anxiety, and effective treatment offered.
Entities:
Keywords:
common mental disorders; comorbidity; drug resistance; epidemiology; infectious disease
Authors: K M Scott; J E Wells; M Angermeyer; T S Brugha; E Bromet; K Demyttenaere; G de Girolamo; O Gureje; J M Haro; R Jin; A Nasser Karam; V Kovess; C Lara; D Levinson; J Ormel; J Posada-Villa; N Sampson; T Takeshima; M Zhang; R C Kessler Journal: Psychol Med Date: 2009-11-26 Impact factor: 7.723
Authors: Anne M Doherty; John Kelly; Colm McDonald; Anne Marie O'Dywer; Joseph Keane; John Cooney Journal: Gen Hosp Psychiatry Date: 2013-05-06 Impact factor: 3.238
Authors: Karen Barnett; Stewart W Mercer; Michael Norbury; Graham Watt; Sally Wyke; Bruce Guthrie Journal: Lancet Date: 2012-05-10 Impact factor: 79.321
Authors: Victoria K Ngo; Adolfo Rubinstein; Vijay Ganju; Pamela Kanellis; Nasser Loza; Cristina Rabadan-Diehl; Abdallah S Daar Journal: PLoS Med Date: 2013-05-14 Impact factor: 11.069